Increasing the cytotoxicity of doxorubicin in breast cancer MCF-7 cells with multidrug resistance using a mesoporous silica nanoparticle drug delivery system

International Journal of Clinical and Experimental Pathology

Volumn 7, Issue 4, 2014, Pages 1337-1347

  Wang, Xin ^a   Teng, Zhaogang ^a   Wang, Haiyan ^a   Wang, Chunyan ^a   Liu, Ying ^a   Tang, Yuxia ^a   Wu, Jiang ^a   Sun, Jin ^a   Wang, Hai ^a   Wang, Jiandong ^a   Lu, Guangming ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

Breast cancer; Drug delivery system; MDR; MSNs

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; MULTIDRUG RESISTANCE PROTEIN; NANOPARTICLE; SILICON DIOXIDE;

ADENOCARCINOMA; ANIMAL; BAGG ALBINO MOUSE; BREAST NEOPLASMS; DISEASE MODEL; DRUG DELIVERY SYSTEM; DRUG EFFECTS; DRUG SCREENING; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MCF 7 CELL LINE; METABOLISM; MOUSE; MULTIDRUG RESISTANCE; NUDE MOUSE; PATHOLOGY; PROCEDURES; TUMOR CELL LINE; UPREGULATION;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DOXORUBICIN; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, MULTIPLE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MCF-7 CELLS; MICE; MICE, INBRED BALB C; MICE, NUDE; NANOPARTICLES; P-GLYCOPROTEIN; SILICON DIOXIDE; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84899494420     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917.
2. Yang X, Uziely B, Groshen S, Lukas J, Israel V, Russell C, Dunnington G, Formenti S, Muggia F and Press MF. MDR1 gene expression in primary and advanced breast cancer. Lab Invest 1999; 79: 271-280.
3. Zyad A, Benard J, Tursz T, Clarke R and Chouaib S. Resistance to TNF-alpha and adriamycin in the human breast cancer MCF-7 cell line: relationship to MDR1, MnSOD, and TNF gene expression. Cancer Res 1994; 54: 825-831.
4. Liu F, Liu S, He S, Xie Z, Zu X and Jiang Y. Survivin transcription is associated with P-glycoprotein/ MDR1 overexpression in the multidrug resistance of MCF-7 breast cancer cells. Oncol Rep 2010; 23: 1469-1475.
5. Xu D, Lu Q and Hu X. Down-regulation of P-glycoprotein expression in MDR breast cancer cell MCF-7/ADR by honokiol. Cancer Lett 2006; 243: 274-280.
6. Mutoh K, Tsukahara S, Mitsuhashi J, Katayama K and Sugimoto Y. Estrogen-mediated post transcriptional down-regulation of P-glycoprotein in MDR1-transduced human breast cancer cells. Cancer Sci 2006; 97: 1198-1204.
7. Tsubaki M, Komai M, Itoh T, Imano M, Sakamoto K, Shimaoka H, Takeda T, Ogawa N, Mashimo K, Fujiwara D, Mukai J, Sakaguchi K, Satou T and Nishida S. By inhibiting Src, verapamil and dasatinib overcome multidrug resistance via increased expression of Bim and decreased expressions of MDR1 and survivin in human multidrug-resistant myeloma cells. Leuk Res 2014; 38: 121-130.
8. Kakumoto M, Sakaeda T, Takara K, Nakamura T, Kita T, Yagami T, Kobayashi H, Okamura N and Okumura K. Effects of carvedilol on MDR1-mediated multidrug resistance: comparison with verapamil. Cancer Sci 2003; 94: 81-86.
9. Gong Y, Han W, Liu J, Chen F, Han J, Jin Y and Yong RO. Synergistic effects of verapamil and anti-mdr1 ribozyme on reversion of multidrug resistance in the P-glycoprotein-positive K562 cell line. Leukemia 2001; 15: 696-697.
10. Abe T, Koike K, Ohga T, Kubo T, Wada M, Kohno K, Mori T, Hidaka K and Kuwano M. Chemosensitisation of spontaneous multidrug resistance by a 1,4-dihydropyridine analogue and verapamil in human glioma cell lines overexpressing MRP or MDR1. Br J Cancer 1995; 72: 418-423.
11. Knezevic NZ and Lin VS. A magnetic mesoporous silica nanoparticle-based drug delivery system for photosensitive cooperative treatment of cancer with a mesopore-capping agent and mesopore-loaded drug. Nanoscale 2013; 5: 1544-1551.
12. Shapira A, Davidson I, Avni N, Assaraf YG and Livney YD. beta-Casein nanoparticle-based oral drug delivery system for potential treatment of gastric carcinoma: stability, target-activated release and cytotoxicity. Eur J Pharm Biopharm 2012; 80: 298-305.
13. Mortera R, Vivero-Escoto J, Slowing II, Garrone E, Onida B and Lin VS. Cell-induced intracellular controlled release of membrane impermeable cysteine from a mesoporous silica nanoparticle-based drug delivery system. Chem Commun (Camb) 2009; 3219-3221.
14. Zhao Y, Trewyn BG, Slowing II and Lin VS. Mesoporous silica nanoparticle-based double drug delivery system for glucose-responsive controlled release of insulin and cyclic AMP. J Am Chem Soc 2009; 131: 8398-8400.
15. Cho Y, Shi R, Borgens RB and Ivanisevic A. Functionalized mesoporous silica nanoparticle-based drug delivery system to rescue acrolein-mediated cell death. Nanomedicine (Lond) 2008; 3: 507-519.
16. Pandey R and Khuller GK. Nanoparticle-based oral drug delivery system for an injectable anti biotic-streptomycin. Evaluation in a murine tuberculosis model. Chemotherapy 2007; 53: 437-441.
17. Pandey R, Sharma A, Zahoor A, Sharma S, Khuller GK and Prasad B. Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J Antimicrob Chemother 2003; 52: 981-986.
18. Zeng X, Morgenstern R and Nystrom AM. Nanoparticle-directed sub-cellular localization of doxorubicin and the sensitization breast cancer cells by circumventing GST-Mediated drug resistance. Biomaterials 2014; 35: 1227-1239.
19. Meng H, Mai WX, Zhang H, Xue M, Xia T, Lin S, Wang X, Zhao Y, Ji Z, Zink JI and Nel AE. Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo. ACS Nano 2013; 7: 994-1005.
20. Kievit FM, Wang FY, Fang C, Mok H, Wang K, Silber JR, Ellenbogen RG and Zhang M. Doxorubicin loaded iron oxide nanoparticles overcome multidrug resistance in cancer in vitro. J Control Release 2011; 152: 76-83.
21. Yang S, Zhao L, Yu C, Zhou X, Tang J, Yuan P, Chen D and Zhao D. On the origin of helical mesostructures. J Am Chem Soc 2006; 128: 10460-10466.
22. Meng H, Yang S, Li Z, Xia T, Chen J, Ji Z, Zhang H, Wang X, Lin S, Huang C, Zhou ZH, Zink JI and Nel AE. Aspect ratio determines the quantity of mesoporous silica nanoparticle uptake by a small GTPase-dependent macropinocytosis mechanism. ACS Nano 2011; 5: 4434-4447.
23. Li Z, Likoko JN, Hwang AA, Ferris DP, Yang S, Derrien G, Charnay C, Durand JO and Zink JI. Measurement of Uptake and Release Capacities of Mesoporous Silica Nanoparticles Enabled by Nanovalve Gates. J Phys Chem C Nanomater Interfaces 2011; 115: 19496-19506.
24. Jia Y, Tian W, Sun S, Han P, Xue W, Li M, Liu Y, Jiang S and Cui B. The influence of genetic polymorphisms in MDR1 gene on breast cancer risk factors in Chinese. Med Oncol 2013; 30: 601.
25. Wen H, Guo J, Chang B and Yang W. pH-responsive composite microspheres based on magnetic mesoporous silica nanoparticle for drug delivery. Eur J Pharm Biopharm 2013; 84: 91-98.